北京若生智能科技有限公司
Drug Database
BR

bromfenac (BromSite / bromfenac, InSite / ISV 303)

✓ Approved

Sun Pharmaceutical Industries Ltd. · PTGS2 · 小分子

什么是 bromfenac？

bromfenac 是一种小分子，由Sun Pharmaceutical Industries Ltd.研发。该药已获批，用于治疗相关适应症，给药途径：Others。

药物档案

商品名BromSite, bromfenac, InSite, ISV 303
公司Sun Pharmaceutical Industries Ltd.
药物类别小分子
分子靶点PTGS2
给药途径Others
状态Approved
来源： ClinicalTrials.gov, Sun Pharmaceutical Industries Ltd.

作用机制

分子靶点

bromfenac 作用于 1 个分子靶点：

PTGS2prostaglandin-endoperoxide synthase 2 (GRIPGHS, hCox-2)
需要更深入的分析？Noah AI 可解释复杂机制并与同类药物比较。

治疗适应症

bromfenac 针对 2 个适应症，涉及 2 个治疗领域。

治疗领域疾病/病症分期
Eye disordersCataract✓ Approved
Injury, poisoning and procedural complicationsProcedural pain✓ Approved

相关研究文献

PubMedGraefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie2026-10-23

Adjunctive topical bromfenac and the 3-year bevacizumab injection burden in macular edema secondary to branch retinal vein occlusion.

Kim Dong Hyeon DH, Lee Jun Ha JH, Kwon Mi Sun MS, Oh Il Joong IJ et al.

Anti-vascular endothelial growth factor therapy for macular edema secondary to branch retinal vein occlusion (BRVO) imposes a substantial long-term injection burden. We evaluated whether eyes prescribed adjunctive topical bromfenac required fewer intravitreal bevacizumab injections over 3 years than those receiving bevacizumab monotherapy. This retrospective, nonconcurrent historical-control cohort study included 62 treatment-naïve eyes followed for 36 months under the same optical coherence tomography (OCT)-guided pro re nata protocol. Twenty-nine eyes received intravitreal bevacizumab alone during 2016-2019, whereas 33 received bevacizumab with adjunctive topical bromfenac during 2023-2026. The adjunctive bromfenac group received fewer injections over 36 months than the bevacizumab monotherapy group (5.8 ± 2.5 vs. 8.9 ± 3.7; p < 0.001) and the association persisted after adjustment for baseline visual acuity, macular thickness, OCT biomarkers, and nonperfusion area (Poisson adjusted rate ratio 0.62; 95% confidence interval 0.50-0.77; p < 0.001). Best-corrected visual acuity and central macular thickness at 36 months did not differ significantly between the two groups. Adjunctive topical bromfenac was associated with fewer bevacizumab injections over 36 months in BRVO-associated macular edema.

PMID 42909592
阅读全文 →
PubMedJournal of vitreoretinal diseases2026-09-30

Effect of Topical Bromfenac 0.09% on Pain Following Intravitreal Antivascular Endothelial Growth Factor Injections.

Achuck Kathryn K, Soares Rebecca R, Solish Danielle D, Popovic Marko M et al.

To evaluate the effect of topical bromfenac 0.09% on pain following intravitreal (IVT) injection of antivascular endothelial growth factor (anti-VEGF) medications in patients diagnosed as having choroidal neovascularization secondary to age-related macular degeneration or other etiologies, diabetic macular edema, diabetic retinopathy, or macular edema associated with retinal vein occlusion. A total of 78 adult patients scheduled to receive bilateral anti-VEGF IVT injections were randomized to receive topical bromfenac 0.09% in 1 eye and artificial tears in the fellow eye (control) immediately before the anti-VEGF treatment at 2 academic institutions from March 2021 to June 2022. Pain was evaluated using the Wong-Baker FACES Pain Rating Scale (score range, 0-10) and the Short-Form McGill Pain Questionnaire (score range, 0-5) at baseline (preinjection) and 5 minutes, 6 hours, and 24 hours following injection. Wilcoxon signed-rank sum test was used for statistical comparisons. In total, 156 eyes were analyzed. Mean baseline pain scores were similar between the bromfenac 0.09% and control groups. Five minutes after injection, eyes randomized to receive bromfenac 0.09% had significantly less pain compared with control eyes receiving artificial tears, on both the Wong-Baker FACES scale (mean raw score, 2.29 vs 2.79; P = .0275) and the McGill Pain Questionnaire (mean raw score, 1.13 vs 2.36; P = .0135). No significant difference in pain scores was noted at 6 hours or 24 hours post-IVT injection. Bromfenac 0.09% solution administered to the study eye before IVT anti-VEGF injection reduced pain 5 minutes after injection in comparison with artificial tears. There was no difference in pain between the 2 groups at 6 hours or 24 hours post-IVT injection.

PMID 42812627
阅读全文 →
PubMedCureus2026-09-19

Incidence and Time to Onset of Pseudophakic Cystoid Macular Edema (Irvine-Gass Syndrome) After 1,325 Consecutive Cataract Surgeries Performed by a Single Surgeon Over Four Years.

Matsuo Toshihiko T, Nakago-Matsuo Chie C

Objectives Macular edema after cataract surgery is known as pseudophakic cystoid macular edema or Irvine-Gass syndrome. The aim of this study was to determine the incidence and time to onset of cystoid macular edema after uncomplicated cataract surgery. Methods  A retrospective review was conducted of 1,325 consecutive cataract surgeries performed by a single surgeon at a single institution over four years, from January 2022 to December 2025. Results Among 1,325 eyes, one or more macular cysts were detected by optical coherence tomography in 27 eyes (2.0%) of 22 patients who complained of blurred vision or decreased visual acuity after having no symptoms immediately after surgery. The 22 patients (27 eyes: 12 right and 15 left) comprised 12 men and 10 women. Their ages at the time of surgery ranged from 57 to 82 years, with a median of 75.5 years. Of the 27 eyes that developed macular cysts, 13 eyes with no preoperative or intraoperative risk factors for inflammation received topical 0.1% bromfenac twice daily as the only postoperative anti-inflammatory treatment, together with topical antibacterial 0.5% moxifloxacin four times daily. In contrast, the remaining 14 eyes, which had risk factors for inflammation, such as exfoliation, floppy iris, poor mydriasis, extracapsular cataract extraction, or diabetes mellitus, received topical bromfenac twice daily and 0.1% betamethasone (or 0.1% fluorometholone in two eyes) four times daily, as well as topical moxifloxacin. The time from surgery to the diagnosis of macular cysts ranged from one week to eight months, with a median of two weeks, in the 13 eyes treated with topical bromfenac only. In the 14 eyes treated with the combination of topical bromfenac and betamethasone, the time to diagnosis ranged from two weeks to 13 months, with a median of two months. In 26 of the 27 eyes, the macular cysts disappeared and visual acuity returned to normal without residual symptoms within two weeks to seven months, with a median of one month, after topical betamethasone four times daily was initiated or resumed. Conclusions  Pseudophakic macular cysts developed during the postoperative course in eyes with no preoperative or intraoperative risk factors that received topical bromfenac alone. They also developed later in the postoperative course after the combination of topical bromfenac and betamethasone was discontinued in eyes with risk factors for inflammation. The macular cysts disappeared following the initiation or resumption of topical betamethasone, accompanied by recovery of visual acuity and resolution of symptoms.

PMID 42762026
阅读全文 →
PubMedSensors (Basel, Switzerland)2026-09-15

An Optimal Receiver Deployment Method for Achieving Robust Localization Performance in Practical Environments.

Park Bosung B, Keun Jongho J, Choo Hosung H

In this paper, we propose a receiver deployment optimization method that ensures robust localization performance under Direction of Arrival (DoA) estimation errors arising in practical environments. The proposed method accounts for DoA estimation errors and optimizes receiver deployments by incorporating Position Dilution of Precision (PDoP) to mitigate their amplification into localization errors. To accurately characterize DoA estimation errors under realistic propagation and installation constraints, a ray-tracing-based Wireless InSite simulator is employed to model environments including actual terrain and buildings. Based on this model, a cost function incorporating both the DoA estimation errors at each receiver and the PDoP is defined, and a Genetic Algorithm (GA) is applied to minimize this cost function and determine the optimal receiver deployment. The optimal deployment achieves low localization RMSE and maintains high robustness against environmental and system uncertainties, particularly when the standard deviation of the DoA estimation error exceeds approximately 8°. These results demonstrate that the proposed deployment method provides reliable localization performance in realistic propagation environments and remains robust against increasing DoA estimation errors.

PMID 42740106
阅读全文 →
PubMedPloS one2026-08-27

Efficacy of a one-week course of topical bromfenac combined with corticosteroid for prevention of pseudophakic cystoid macular edema (PCME).

Kim Yoon Soo YS, Song Myung-Sun MS, Eom Young Sub YS, Song Jong Suk JS et al.

To compare the efficacy of a 1-week postoperative regimen of topical bromfenac combined with corticosteroid versus corticosteroid monotherapy in preventing pseudophakic cystoid macular edema (PCME). This retrospective study included 226 eyes of 226 patients who underwent uneventful phacoemulsification. Patients were divided into Group A (n = 158), receiving topical bromfenac 0.1% twice daily (BID) plus prednisolone acetate 1% (PDE) 6 times daily (6/d) or every 2 hours while awake (q2hrs), and Group B (n = 68), receiving PDE alone 6/d or q2hrs for the first postoperative week. Macular thickness was measured by Spectral-domain optical coherence tomography (SD-OCT) preoperatively and at postoperative week 5. PCME was defined as an increase in central subfield macular thickness (CSMT) with foveal cystoid changes. CSMT changes and PCME incidence were compared. A subgroup analysis evaluated the effect of PDE dosing frequency within the combination arm (6/d vs. q2hrs). Postoperative absolute and relative CSMT changes were significantly smaller in Group A (13.3 ± 13.0 μm, 5.6 ± 5.3%) than in Group B (27.0 ± 33.7 μm, 11.2 ± 14.3%; p = 0.002). The incidence of OCT-defined PCME was lower in Group A than in Group B (5.1% vs. 16.2%; OR = 0.28; 95% CI 0.11-0.72; p = 0.006). Among eyes developing PCME, the median CSMT increase was lower in Group A (38.5 μm) than in Group B (80.0 μm; p = 0.031). PCME incidence was numerically lower in [Bromfenac BID + PDE q2hrs] subgroup than [Bromfenac BID + PDE 6/d] subgroup (2.0% vs. 10.0%, OR = 0.19; 95% CI 0.04-0.79; p = 0.054). A one-week course of topical bromfenac combined with topical corticosteroid therapy was associated with smaller postoperative increases in macular thickness and a lower incidence of OCT-defined PCME than corticosteroid monotherapy after cataract surgery.

PMID 42658891
阅读全文 →
PubMedRSC advances2026-08-08

Sustainable spectrophotometric fingerprinting resolution technique for concurrent quantification of ofloxacin and bromfenac in rabbit aqueous humor with ocular pharmacokinetic application.

Khafagy El-Sayed ES, Abu Lila Amr Selim AS, Al Saqr Ahmed A, Aldawsari Mohammed F MF et al.

The simultaneous quantification of multiple drugs in biological matrices is crucial for therapeutic drug monitoring and pharmacokinetic studies. A sustainable spectrophotometric fingerprinting resolution technique was developed for the simultaneous determination of ofloxacin (OFL) and bromfenac (BMF) in rabbit aqueous humor. The technique manipulates spectral data to extract the original zero-order absorption spectrum (D 0) of each analyte from overlapping signals in the mixture. This approach relies on the ratio subtraction method (RSM) combined with one or more additional methods, including extended ratio subtraction (ERS), unified constant subtraction (UCS), constant multiplication (CM), or spectrum subtraction (SS). Validation per ICH-Q2R1 showed a linearity range of 1-16 µg mL-1 for both drugs, with LOD/LOQ values between 0.16 and 0.63 µg mL-1. Following a simple protein-precipitation step, the technique was successfully applied to spiked rabbit aqueous humor samples, with recoveries between 97.8% and 102.1%. Matrix effect assessment confirmed negligible interference, with ME% values of -1.12% (OFL) and -0.98% (BMF). The validated technique was then used in an ocular pharmacokinetic study in rabbits following a single topical instillation of a combined OFL-BMF ophthalmic solution. The concentration-time profiles of both drugs in aqueous humor were effectively characterized, and key pharmacokinetic parameters were determined. Sustainability assessment indicated excellent trichromatic scores, confirming their suitability for ocular matrix analysis. This technique offers a sustainable platform for analyzing OFL and BMF in biological fluids, making it highly valuable for ocular bioavailability and pharmacokinetic studies.

PMID 42569095
阅读全文 →

注册免费账户还可查看另外 419 篇文献

免费注册查看全部文献 →

了解更多bromfenac